Co-located cell types help drive aggressive brain tumors, study finds
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...
Armed robbery in Revesby4h
Cell Types Co-located Drive Aggressive Brain Tumors
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...
The American Journal of Managed Care22h
Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) ...
Managed Healthcare Executive1d
Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients
Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.
News Medical on MSN13d
Researchers pinpoint keys to cell therapy response for leukemia
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...
Medindia13d
Keys to Effective Leukemia Cell Therapies Identified
Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...
'My brother saved my life on Christmas Eve'
Mr Claxton was in hospital over Christmas, receiving the transplant on Christmas Eve, and said he was now in recoveery. He is ...
BioTechniques1d
Why do some AML patients respond better to immunotherapy?
Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.